Developing ecopipam, a dopamine D-1 antagonist, for the treatment of Tourette's syndrome, a neurological disorder manifested by motor and phonic tics.

Sectors
Healthcare
Life Sciences
First Invested
2004
Early
Company Status
Acquired
Acquired by Emalex
Associated Team
Michael Albert